[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634271":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":18,"locations":26,"responsibleParty":43,"collaborators":46,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":7,"enrollmentInfo":61,"targetDuration":64,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Hospital General Universitario Gregorio Marañon","OTHER",null,[9,13,16],{"name":10,"affiliation":11,"role":12},"Ana I Fernandez-Avila, PhD","Institoto de Investigación Gregorio Marañón","PRINCIPAL_INVESTIGATOR",{"name":14,"affiliation":15,"role":12},"Carlos Ortiz, MD, PhD","Hospital GU Gregorio Marañón",{"name":17,"affiliation":15,"role":12},"Jorge Martinez-Solano, MD; PhD",[19,23],{"name":10,"role":20,"phone":21,"phoneExt":7,"email":22},"CONTACT","+34650413943","afernandeza.externo@salud.madrid.org",{"name":24,"role":20,"phone":7,"phoneExt":7,"email":25},"Jorge Martinez-Solano, MD, PhD","jmsolano@salud.madrid.org",[27],{"facility":15,"status":28,"city":29,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Madrid","28007","Spain","ES",{"type":34,"coordinates":35},"Point",[36,37],-3.70256,40.4165,{"lat":37,"lon":36},[40,42],{"name":24,"role":20,"phone":41,"phoneExt":7,"email":25},"+3466294110",{"name":14,"role":20,"phone":7,"phoneExt":7,"email":7},{"type":12,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Javier Bermejo Thomas","Research Group Leader",[47,49],{"name":48,"class":6},"Fundacion para la Innovacion en Biomedicina (FIBMED)",{"name":50,"class":6},"Instituto de Investigación Sanitaria Gregorio Marañón","100634271","evaluation-of-the-bmpr2-activin-signaling-pathway-in-group-ii-pulmonary-hypertension-100634271",false,"NCT07537517","Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.","Evaluation of the BMPR2-Activin Signaling Pathway as a Key Mediator in Group II Pulmonary Hypertension. BREATHE-PH Study","BREATHE-PH","Inclusion Criteria:\n\n* Older that 18 years\n* Heart failled patients with clinical indication for invasive hemodynamic assessment\n* Written consent\n\nExclusion Criteria:\n\n* Refulsl to sign the infomred consent\n* Presence of iodinated contrast allergy\n* Ineligibility for HT (for BREATHE-CT substudy)","ALL","18 Years",{"count":62,"type":63},150,"ESTIMATED","12 Months","OBSERVATIONAL","Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin.\n\nFocusing on dysregulation of the BMPR2-activin pathway, a key regulator of vascular homeostasis, this project uses a multimodal approach combining molecular biology, advanced cardiac imaging, and histology.\n\nIts aim is to determine the role of the BMPR2-activin pathway in the development and regression of PH-LHD.\n\nWe will conduct a prospective observational study with 1-year follow-up in 150 heart failure patients of different etiologies undergoing hemodynamic assessment.\n\nClinical parameters, biomarkers, molecular profiles, and hemodynamic\u002Fechocardiographic variables will be analyzed.\n\nA nested substudy in 40 heart transplant candidates will include thoracic CT for vascular morphometric analysis and histological correlation in explanted hearts versus healthy controls.\n\nWe will also assess reversibility of vascular remodeling one year after transplantation.\n\nResults may redefine PH-LHD classification, enable phenotypic precision-medicine models, guide targeted therapies such as activin inhibitors, and refine transplant criteria in combined pulmonary hypertension.",[68,69,70],"Pulmonary Hypertension Due to Left Heart Disease","Pulmonary Hypertension (PH)","Heart Failure",[72,73,74,75,76,77],"BMPR2","Activin","cardiac transplant","pulomnary hypertension II","gene expression","microRNAs","2026-04-16",{"date":80,"type":81},"2026-04-17","ACTUAL",{"date":83,"type":81},"2025-11-01",{"date":85,"type":63},"2028-12-31",{"name":5,"class":6},1]